Bi- & Multispecific Molecular Design with Improved Therapeutic Windows through Rational Target Pairing
- Highlighting differentiated target identification for first-in-class multispecific drugs
- Benchmarking to known approved TCE drugs
- Leveraging dual targeting to expand therapeutic window and patient prevalence